Articles by Anna Rose Welch

  1. What “Unboiling” An Egg Can Mean For Cancer Drug Development 1/28/2015

    In a strange and exciting twist, researchers from the University of California, Irvine (UCI) and Flinders University announced this week they have discovered a new way to “unboil” a hen’s egg — a task that could have huge ramifications for the biotech industry as it races to get cancer meds to patients faster.

  2. The Drug Price War Hits Vaccines: Will Pfizer, GSK Give In To MSF Plea? 1/22/2015

    A new pricing war is afoot — but this time, it doesn’t involve AbbVie or Gilead Science’s HCV treatments. This week, Pfizer and GSK were both met with push-back from Doctors Without Borders (MSF) to reduce the prices of their pneumococcal vaccines to $5 per child (includes all three doses).

  3. So, You Want To Be Top Earning Healthcare CEO? Shoot For Biopharma 1/21/2015

    In 2012, Pfizer’s CEO Ian Read held the title of being the highest-paid CEO of a large pharmaceutical company, bringing roughly $26 million to the bank. His salary was $21 million more than the lowest paid large pharmaceutical CEO, NovoNordisk’s Lars Rebien Soerensen, who earned $5 million, Bloomberg reported in the spring of 2013. However, some more numbers released in June of 2014 are showing that, in 2013, Pfizer’s Read stepped aside and earned less than what several of his CEO peers in the biopharma space are making, even though Pfizer raked in $52 billion in revenue for the year.

  4. The 2015 NSCLC Immunotherapy Race Is Already Narrowing 1/20/2015

    It’s been a productive beginning of the year in the realm of immunotherapy. Recent headlines have boasted news about some major players making waves in immunotherapy — especially in the NSCLC treatment area —  which will not only benefit a large number of patients, but will also give productive players a slice of what’s expected to be a very lucrative market.  

  5. Pharma News Roundup: Amgen, Isis, Janssen, Pfizer, Novartis, And More 1/14/2015

    In recent news, stem cell research is taking the forefront as new collaborations speed up the development of CRISPR immunotherapies; Cempra is moving forward in its development of a next-generation antibiotic; and a new antisense drug could be a game-changer for autoimmune disorders of the GI tract.

  6. “Hyper-Innovation” In Pharma: FDA Approvals Are Just The Start 1/14/2015

    It’s clear, after 2014's surge in FDA approvals, that the industry has increased its productivity. Pharma is slowly clawing its way out of what Forbes has labeled the “painful trough” of 2005-2010. But what do these recent approvals tell us about where we are headed — or where we need to be headed — as an industry?

  7. “Pharmaficial” Intelligence: Could Science Fiction Become A Pharma Reality? 1/14/2015

    All the buzz about wearable technology and the convergence of Google and pharma this past year has made me think about where technology is carrying our industry.

  8. Merck Snaps Up Cubist: Will 2015 Be The Antibiotics Renaissance? 1/7/2015

    2014 was a big year for acquisitions. However, two other 2014 acquisitions suggest to me that Big Pharma might be planning to tackle an increasingly urgent unmet health need in 2015.

  9. EMA, NICE, EC News Roundup: Roche, Boehringer Ingelheim, AstraZeneca, And More 10/27/2014

    Kadcyla has once again been rejected for inclusion on the NHS in another country on the grounds of its price. Anna Rose Welch

  10. EMA, CHMP, NICE News Roundup: AstraZeneca, Gilead, Novartis, And More 10/3/2014

    AstraZeneca received several articles of good news from European regulators recently. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for Moventig (naloxegol) for patients with opioid-induced constipation (OIC) who have not been successfully treated with laxatives.